Linda Bel Haj Kacem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Linda Bel Haj Kacem has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Soumaya Rammeh
Department of Pathology, Charles Nicolle Hospital, Tunis, Tunisia; LR23ES02, Faculté de Médecine de Tunis, Université de Tunis El Manar, Tunis, Tunisia
2 shared publications - Abada Mhamdi
Laboratory of Population Health, Environmental Aggressors and Alternative Therapies (LR24ES10), Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis 1007, Tunisia
1 shared publication - Afef Nahdi
Laboratory of Population Health, Environmental Aggressors and Alternative Therapies (LR24ES10), Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis 1007, Tunisia
1 shared publication - Ahlem Blel
Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia
1 shared publication - Ahmed Saadi
Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia
1 shared publication - Aicha Ben Tekaya
Rheumatology department, Charles Nicolle hospital, Tunis, Tunisia
1 shared publication
Latest Publications
- Open Access
Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability
Background: Despite clinical and pathological risk tools, predicting outcomes in non-muscle-invasive bladder cancer (NMIBC), particularly high-grade (HG) cases, remains challenging due to its unpredictable recurrence and progression. There is an urgent need for molecular biomarkers to enhance risk stratification and guide treatment. Methods: We assessed the prognostic potential of eight miRNAs (miR-9, miR-143, miR-182, miR-205, miR-27a, miR-369, let-7c, and let-7g) in a cohort of ninety patients with primary bladder cancer. Expression data were retrieved from our previously published studies. Kaplan–Meier’s and Cox’s regression analyses were used to evaluate the associations with overall survival (OS), metastasis-free survival (MFS), and clinical outcomes. Principal component analysis (PCA) was performed to identify informative miRNA combinations. Target gene prediction, pathway enrichment (DAVID), and drug–gene interaction mapping (DGIdb) were conducted in silico. Results: A high expression of let-7g and miR-9 was significantly associated with better OS in HG NMIBC and MIBC, respectively (p = 0.013 and p = 0.000). MiR-9 downregulation correlated with metastasis in MIBC (p = 0.018). Among all combinations, miR-205 and miR-27a best predicted intermediate-risk NMIBC progression and recurrence (r2 = 0.982, p = 0.000). A functional analysis revealed that these miRNAs regulate key cancer-related pathways (MAPK, mTOR, and p53) through genes such as TP53, PTEN, and CDKN1A. Drug interaction mapping identified nine target genes (e.g., DAPK1, ATR, and MTR) associated with eight FDA-approved bladder cancer therapies, including cisplatin and gemcitabine. Conclusions: Let-7g, miR-9, miR-143, miR-182, and miR-205 emerged as promising biomarkers for outcome prediction in NMIBC. Their integration into liquid biopsy platforms could support non-invasive monitoring and personalized treatment strategies. These findings warrant validation in larger, prospective studies and through functional assays.
Open AccessDysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability
Background: Despite clinical and pathological risk tools, predicting outcomes in non-muscle-invasive bladder cancer (NMIBC), particularly high-grade (HG) cases, remains challenging due to its unpredictable recurrence and progression. There is an urgent need for molecular biomarkers to enhance risk stratification and guide treatment. Methods: We assessed the prognostic potential of eight miRNAs (miR-9, miR-143, miR-182, miR-205, miR-27a, miR-369, let-7c, and let-7g) in a cohort of ninety patients with primary bladder cancer. Expression data were retrieved from our previously published studies. Kaplan–Meier’s and Cox’s regression analyses were used to evaluate the associations with overall survival (OS), metastasis-free survival (MFS), and clinical outcomes. Principal component analysis (PCA) was performed to identify informative miRNA combinations. Target gene prediction, pathway enrichment (DAVID), and drug–gene interaction mapping (DGIdb) were conducted in silico. Results: A high expression of let-7g and miR-9 was significantly associated with better OS in HG NMIBC and MIBC, respectively (p = 0.013 and p = 0.000). MiR-9 downregulation correlated with metastasis in MIBC (p = 0.018). Among all combinations, miR-205 and miR-27a best predicted intermediate-risk NMIBC progression and recurrence (r2 = 0.982, p = 0.000). A functional analysis revealed that these miRNAs regulate key cancer-related pathways (MAPK, mTOR, and p53) through genes such as TP53, PTEN, and CDKN1A. Drug interaction mapping identified nine target genes (e.g., DAPK1, ATR, and MTR) associated with eight FDA-approved bladder cancer therapies, including cisplatin and gemcitabine. Conclusions: Let-7g, miR-9, miR-143, miR-182, and miR-205 emerged as promising biomarkers for outcome prediction in NMIBC. Their integration into liquid biopsy platforms could support non-invasive monitoring and personalized treatment strategies. These findings warrant validation in larger, prospective studies and through functional assays.
- Open Access
- 2 June 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 546
Case Report: Pure Encapsulated Papillary Carcinoma of the Breast in a Centenarian: A Case Report of Distant Metastasis After Surgery, and review of literature
Background Breast cancer in elderly patients, particularly in centenarians, presents unique diagnostic and therapeutic challenges. Encapsulated papillary carcinoma (EPC) is a rare subtype that typically exhibits indolent behavior, but its aggressive course remains poorly understood. This report describes an exceptional case of EPC in a 102-year-old woman with a rapid metastatic progression. Case Presentation A 102-year-old female with hypertension presented with a one-year history of a progressively enlarging, left-sided breast mass. Imaging revealed a 28 cm cystic mass with a 14 cm intracystic nodule. Biopsy confirmed ER-positive, PR-negative, HER2-negative encapsulated papillary carcinoma (T3N0M0). Mastectomy with axillary dissection revealed a 13 cm tumor with close surgical margins (<0.5 mm). The final histologic examination concluded to a pure EPC. Three months postoperatively, metastatic lesions in the sternum and liver were identified. Despite initiating letrozole and CDK4/6 inhibitor therapy, the patient succumbed to cardiac arrest. Conclusion The case of a 102-year-old female with EPC of the breast illustrates several unique and clinically significant features, including the rarity of metastasis, exceptional tumor size, and implications of advanced age on the disease course and management. This case study in accordance with the CARE guidelines.
- 2 June 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 546
Open AccessCase Report: Pure Encapsulated Papillary Carcinoma of the Breast in a Centenarian: A Case Report of Distant Metastasis After Surgery, and review of literature
Background Breast cancer in elderly patients, particularly in centenarians, presents unique diagnostic and therapeutic challenges. Encapsulated papillary carcinoma (EPC) is a rare subtype that typically exhibits indolent behavior, but its aggressive course remains poorly understood. This report describes an exceptional case of EPC in a 102-year-old woman with a rapid metastatic progression. Case Presentation A 102-year-old female with hypertension presented with a one-year history of a progressively enlarging, left-sided breast mass. Imaging revealed a 28 cm cystic mass with a 14 cm intracystic nodule. Biopsy confirmed ER-positive, PR-negative, HER2-negative encapsulated papillary carcinoma (T3N0M0). Mastectomy with axillary dissection revealed a 13 cm tumor with close surgical margins (<0.5 mm). The final histologic examination concluded to a pure EPC. Three months postoperatively, metastatic lesions in the sternum and liver were identified. Despite initiating letrozole and CDK4/6 inhibitor therapy, the patient succumbed to cardiac arrest. Conclusion The case of a 102-year-old female with EPC of the breast illustrates several unique and clinically significant features, including the rarity of metastasis, exceptional tumor size, and implications of advanced age on the disease course and management. This case study in accordance with the CARE guidelines.
- Open Access
In-Depth Analysis of Olea europaea L. Leaf Extract: Alleviating Pulmonary Histological Disturbances, Pro-Inflammatory Responses, and Oxidative Stress from Isolated or Combined Exposure to Inhaled Toluene and Noise in Rats
The primary objective of this study was to investigate the pulmonary damage resulting from isolated or combined exposure to inhaled toluene (300 ppm) and noise 85 dB (A), with a focus on evaluating the potential protective effects of Olea europaea L. leaf extract (OLE). Forty-eight male Wistar rats were divided into eight groups: control (C), OLE treatment (O), noise exposure (N), noise exposure with OLE treatment (N+OLE), toluene exposure (T), toluene exposure with OLE treatment (T + OLE), co-exposure to toluene and noise (NT), and co-exposure with OLE treatment (NT + OLE). OLE (40 mg/kg/day) was administered daily for six weeks via oral gavage. Exposure to toluene and noise resulted in significant disruption of the pulmonary tissue structure, accompanied by oxidative stress, as evidenced by increased lipid peroxidation, diminished catalase and superoxide dismutase activities, and elevated pro-inflammatory cytokines IL6, IL-β, and TNF-α. Notably, the administration of OLE effectively mitigated oxidative stress and inflammation and preserved pulmonary histology. In conclusion, exposure to toluene and its combination with noise significantly elevated oxidative stress, inflammatory responses, and histological disruptions in the lung tissue. In contrast, noise exposure alone is characterized by minimal effects, although it is still associated with an inflammatory response. Notably, Olea europaea L. leaf extract (OLE) exhibits a substantial protective role, effectively mitigating the adverse effects of combined exposure and highlighting its potential as a therapeutic agent for lung health.
Open AccessIn-Depth Analysis of Olea europaea L. Leaf Extract: Alleviating Pulmonary Histological Disturbances, Pro-Inflammatory Responses, and Oxidative Stress from Isolated or Combined Exposure to Inhaled Toluene and Noise in Rats
The primary objective of this study was to investigate the pulmonary damage resulting from isolated or combined exposure to inhaled toluene (300 ppm) and noise 85 dB (A), with a focus on evaluating the potential protective effects of Olea europaea L. leaf extract (OLE). Forty-eight male Wistar rats were divided into eight groups: control (C), OLE treatment (O), noise exposure (N), noise exposure with OLE treatment (N+OLE), toluene exposure (T), toluene exposure with OLE treatment (T + OLE), co-exposure to toluene and noise (NT), and co-exposure with OLE treatment (NT + OLE). OLE (40 mg/kg/day) was administered daily for six weeks via oral gavage. Exposure to toluene and noise resulted in significant disruption of the pulmonary tissue structure, accompanied by oxidative stress, as evidenced by increased lipid peroxidation, diminished catalase and superoxide dismutase activities, and elevated pro-inflammatory cytokines IL6, IL-β, and TNF-α. Notably, the administration of OLE effectively mitigated oxidative stress and inflammation and preserved pulmonary histology. In conclusion, exposure to toluene and its combination with noise significantly elevated oxidative stress, inflammatory responses, and histological disruptions in the lung tissue. In contrast, noise exposure alone is characterized by minimal effects, although it is still associated with an inflammatory response. Notably, Olea europaea L. leaf extract (OLE) exhibits a substantial protective role, effectively mitigating the adverse effects of combined exposure and highlighting its potential as a therapeutic agent for lung health.
- 27 September 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (1) , 285-291
Tophaceous gout in a young man with Gitelman syndrome: a case report with an overview
Gitelman syndrome represents the clinical manifestations of inactivation of the Slc12a3 genes encoding the thiazide-sensitive sodium chloride cotransporter and the Trpm6-Mg genes encoding the magnesium transporters in the distal convoluted tubule. In fact, the biochemical findings resemble those with thiazide diuretics such as hypokalemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis, and low normal blood pressure. He is usually associated with calcium pyrophosphate deposition. Serum uricemia level is rarely affected in Gitelman syndrome. We aimed to report a rare association of chronic gout with Gitelman syndrome, hence the interest of our case. We describe a 29-year-old male patient with a history of Gitelman syndrome associated with articular gout including pelvic localization. We provided pictorial evidence of extensive and diffuse monosodium urate deposition in articular and periarticular structures to confirm the gout origin. A literature review illustrates 4 reported cases of Gitelman syndrome associated with gout. The gender distribution was equal with a mean age of 40 years. Key Points • Gouty arthritis and Gitelman syndrome is a rare association. • Gitelman syndrome may be a new risk factor for the development of gout, due to its thiazide-like effect.
- 27 September 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (1) , 285-291
Tophaceous gout in a young man with Gitelman syndrome: a case report with an overview
Gitelman syndrome represents the clinical manifestations of inactivation of the Slc12a3 genes encoding the thiazide-sensitive sodium chloride cotransporter and the Trpm6-Mg genes encoding the magnesium transporters in the distal convoluted tubule. In fact, the biochemical findings resemble those with thiazide diuretics such as hypokalemia, hypomagnesaemia, hypocalciuria, metabolic alkalosis, and low normal blood pressure. He is usually associated with calcium pyrophosphate deposition. Serum uricemia level is rarely affected in Gitelman syndrome. We aimed to report a rare association of chronic gout with Gitelman syndrome, hence the interest of our case. We describe a 29-year-old male patient with a history of Gitelman syndrome associated with articular gout including pelvic localization. We provided pictorial evidence of extensive and diffuse monosodium urate deposition in articular and periarticular structures to confirm the gout origin. A literature review illustrates 4 reported cases of Gitelman syndrome associated with gout. The gender distribution was equal with a mean age of 40 years. Key Points • Gouty arthritis and Gitelman syndrome is a rare association. • Gitelman syndrome may be a new risk factor for the development of gout, due to its thiazide-like effect.
- Open Access
- 26 April 2022
- Published by Wiley
Multiple keratoacanthomas of Ferguson-Smith type
We report a case of a 41-year-old male patient with no family history, presented with extensive multiple keratoacanthomas with disfiguring scars. The diagnosis of a sporadic form of Ferguson-Smith syndrome was made. Treatment with acitretin showed a marked response. Recognizing this syndrome is crucial, early treatment helps avoid scar format
- 26 April 2022
- Published by Wiley
Open AccessMultiple keratoacanthomas of Ferguson-Smith type
We report a case of a 41-year-old male patient with no family history, presented with extensive multiple keratoacanthomas with disfiguring scars. The diagnosis of a sporadic form of Ferguson-Smith syndrome was made. Treatment with acitretin showed a marked response. Recognizing this syndrome is crucial, early treatment helps avoid scar format